A first-of-its-kind national platform honouring the people and institutions shaping the next chapter of life sciences in India
Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence
_256_384.jpg)
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
The program will offer a structured and immersive learning experience for over 20,000 healthcare professionals across more than 10 cities
Adults taking Mounjaro with diet and exercise in a controlled clinical trial lost on average 21.8 kg at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg)
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
